-
Oseltamivir (tamiflu®) is an fda-approved drug for the treatment and prevention of influenza.
-
Epidemiologists have pondered the possible environmental source for sporadic cases of legionella infection in humans.
-
Artemisinins are the most rapidly acting antimalarials available, have few serious side effects, and have been used extensively with few reports of resistance until recently.
-
Typhoid fever sickens more than 16 million people worldwide and causes up to 600,000 deaths annually, mostly in developing countries.
-
A randomized, double-blind, placebo-controlled, multicenter study was conducted from 2002-2006 at 25 institutions in France of the effect of prophylactic recombinant granulocyte-colony stimulating factor (rG-CSF) on nosocomial infections and survival among preterm neonates with persistent neutropenia.
-
The 2009 update of hiv primary care guidelines make several new recommendations, and the evidence basis for these is documented in the paper.
-
n this issue: WHO recommendations for antiviral use for H1N1 flu; antibiotic use trends for acute respiratory tract infection; denosumab clears FDA Expert Panel; FDA Actions.
-
-
A population-based telephone survey was conducted among residents < 20 years of age in Antelope Valley, CA, from 2000 through 2006. During this period, 459 evaluable cases of herpes zoster among persons < 20 years of age were reported.
-
Patients eligible for EFV-based haart (EFV plus two nucleoside RT inhibitors) were randomized to EFV in an escalating dose over two weeks vs. standard 600 mg/d dosing. NPAEs and sleep quality were assessed by questionnaires over the first 30 days of therapy.
